Diabetic technology makes a leap into the future

Cara Livernois | | Health Exec | Economics

Advancements in technology have opened new possibilities in diabetes management—and companies around the world are vying for a piece of the pie.

Silicon Valley has been exploring avenues into healthcare in many ways, but advancements in diabetes management are poised to make an impact in self-regulating chronic diseases. Replacing fingerpricks with continuous monitoring and inaccurate blood sugar measurements with sensor readings, these technologies are enabling patients to take charge of their own care.

“Companies who succeed will be those who can figure out this convergence of health care and technology,” said Arda Ural, a partner at Ernst & Young LLP in New York. “And they’re very different animals to bring together.”

Read the full story below:

U.S. Diabetes Patients Are About to Get Some High-Tech Relief

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Walgreens $10B private equity buyout financed by 83% debt
Walgreens confirms $10B sale to PE, as part of $24B transaction
5 ways AI can help make healthcare more affordable for everyone
More than 1,000 hospitals earn $700M opioid crisis judgment
Building a successful CCTA program: Physicians and healthcare executives to share advice
VA planning 83,000 layoffs as part of restructuring

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.